{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T23:09:21Z","timestamp":1790118561035,"version":"4.0.1"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Crohn's and Colitis"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1016\/j.crohns.2012.02.017","type":"journal-article","created":{"date-parts":[[2012,4,4]],"date-time":"2012-04-04T16:45:23Z","timestamp":1333557923000},"page":"34-43","source":"Crossref","is-referenced-by-count":51,"title":["Adalimumab improves patient-reported outcomes and reduces indirect costs in patients with moderate to severe Crohn's disease: Results from the CARE trial"],"prefix":"10.1093","volume":"7","author":[{"given":"Edouard","family":"Louis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"L\u00f6fberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Reinisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Camez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul F.","family":"Pollack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naijun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingdong","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parvez M.","family":"Mulani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"10.1016\/j.crohns.2012.02.017_bb0005","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/ajg.2008.168","article-title":"Management of Crohn's disease in adults","volume":"104","author":"Lichtenstein","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.crohns.2012.02.017_bb0010","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/01.mcg.0000159220.70290.41","article-title":"Unemployment and disability in patients with moderately to severely active Crohn's disease","volume":"39","author":"Feagan","year":"2005","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.crohns.2012.02.017_bb0015","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.3109\/00365529709002993","article-title":"Inflammatory bowel diseases: health care and costs in Sweden in 1994","volume":"32","author":"Blomqvist","year":"1997","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.crohns.2012.02.017_bb0020","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1046\/j.1572-0241.2003.04010.x","article-title":"Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries","volume":"99","author":"Lichtenstein","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.crohns.2012.02.017_bb0025","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1046\/j.1365-2036.2002.01140.x","article-title":"The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systemic review","volume":"16","author":"Loftus","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.crohns.2012.02.017_bb0030","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2036.2006.03134.x","article-title":"Review article: altering the natural history of Crohn's disease \u2014 evidence for and against current therapies","volume":"25","author":"Vermeire","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.crohns.2012.02.017_bb0035","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/01.meg.0000243883.47938.aa","article-title":"Relationship between clinical features of Crohn's disease and the risk of developing extraintestinal manifestations","volume":"19","author":"Barreiro-de Acosta","year":"2007","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.crohns.2012.02.017_bb0040","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s11938-007-0012-4","article-title":"Pharmacoeconomics and quality of life of current and emerging biologic therapy for inflammatory bowel disease","volume":"10","author":"Zisman","year":"2007","journal-title":"Curr Treat Options Gastroenterol"},{"key":"10.1016\/j.crohns.2012.02.017_bb0045","doi-asserted-by":"crossref","first-page":"797","DOI":"10.2165\/00019053-200624080-00006","article-title":"Costs of inflammatory bowel disease in Germany","volume":"24","author":"Stark","year":"2006","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.crohns.2012.02.017_bb0050","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1111\/j.1572-0241.2000.02261.x","article-title":"Annual cost of care for Crohn's disease: a payor perspective","volume":"95","author":"Feagan","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.crohns.2012.02.017_bb0055","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1185\/030079908X260790","article-title":"The costs of Crohn's disease in the United States and other Western countries: a systematic review","volume":"24","author":"Yu","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.crohns.2012.02.017_bb0060","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1002\/ibd.20939","article-title":"Resource use and societal costs for Crohn's disease in Sweden","volume":"15","author":"Mesterton","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2012.02.017_bb0065","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/j.1365-2036.2010.04303.x","article-title":"Clinical trial: the effects of certolizumab pegol therapy on work productivity in patients with moderate-to-severe Crohn's disease in the PRECiSE 2 study","volume":"31","author":"Feagan","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl. 3","key":"10.1016\/j.crohns.2012.02.017_bb0070","doi-asserted-by":"crossref","first-page":"S462","DOI":"10.14309\/00000434-200910003-01238","article-title":"Work productivity improvements in adalimumab-treated patients with moderate to severe ileocolonic Crohn's disease: the EXTEND trial","volume":"104","author":"Binion","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.crohns.2012.02.017_bb0075","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1111\/j.1365-2036.2010.04466.x","article-title":"The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life, and increased work productivity in patients with Crohn's disease who failed prior infliximab therapy","volume":"32","author":"Lichtiger","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.crohns.2012.02.017_bb0080","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/j.1365-2036.2010.04568.x","article-title":"Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn's disease with prior loss of response to infliximab","volume":"33","author":"Feagan","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.crohns.2012.02.017_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ibd.21663","article-title":"Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn's disease: results from CARE","volume":"18","author":"Lofberg","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2012.02.017_bb0090","first-page":"1571","article-title":"The Short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn's Relapse Prevention Trial","volume":"91","author":"Irvine","year":"1996","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.crohns.2012.02.017_bb0095","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","article-title":"The validity and reproducibility of a work productivity and activity impairment instrument","volume":"4","author":"Reilly","year":"1993","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.crohns.2012.02.017_bb0100","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.clinthera.2008.02.016","article-title":"Validity, reliability, and responsiveness of the Work Productivity and Activity Impairment questionnaire in Crohn's disease","volume":"30","author":"Reilly","year":"2008","journal-title":"Clin Ther"},{"issue":"Suppl. 3","key":"10.1016\/j.crohns.2012.02.017_bb0105","first-page":"A159","article-title":"Defining the minimally important difference for WPAI: CD scores: What is a relevant impact on work productivity in active Crohn's disease?","volume":"56","author":"Reilly","year":"2007","journal-title":"Gut"},{"key":"10.1016\/j.crohns.2012.02.017_bb0110","author":"European Commission"},{"key":"10.1016\/j.crohns.2012.02.017_bb0115","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1111\/j.1572-0241.2008.02175.x","article-title":"Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial","volume":"103","author":"Loftus","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.crohns.2012.02.017_bb0120","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1111\/j.1572-0241.2003.07674.x","article-title":"The effects of infliximab maintenance therapy on health-related quality of life","volume":"98","author":"Feagan","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.crohns.2012.02.017_bb0125","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/0016-5085(94)90585-1","article-title":"Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group","volume":"106","author":"Irvine","year":"1994","journal-title":"Gastroenterology"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1873994612000931?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1873994612000931?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/7\/1\/34\/1119505\/7-1-34.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T20:02:45Z","timestamp":1713816165000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-lookup\/doi\/10.1016\/j.crohns.2012.02.017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["S1873994612000931"],"URL":"https:\/\/doi.org\/10.1016\/j.crohns.2012.02.017","relation":{},"ISSN":["1873-9946"],"issn-type":[{"value":"1873-9946","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]}}}